Literature DB >> 18053050

A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.

Doris Hexsel1, Taciana Dal'Forno, Camile Hexsel, Débora Zechmeister Do Prado, Maryelle Moreira Lima.   

Abstract

BACKGROUND: The determination of the action halos of botulinum toxin type A aids in targeting specific muscles and/or sweat glands, thereby preventing the occurrence of side effects.
OBJECTIVES: The objective of this study was to compare the action halos of two commercial preparations of botulinum toxin type A, Dysport (Ipsen, Slough, UK) and BOTOX (Allergan, Irvine, CA).
MATERIAL AND METHODS: Eighteen volunteers received applications of both products into randomized sides of the frontalis muscle. Equivalent doses of 5 U of Dysport and 2 U of BOTOX were injected using the same technique, in the same volume (0.02 mL), and at a controlled depth. Twenty-eight days later, clinical and photographic assessments were performed.
RESULTS: All the areas around the injected points were regular, round, or slightly oval and showed similar effects in the muscles and sweat glands. No statistically significant differences were observed between the mean sizes of the diameters of the halos produced by the two products.
CONCLUSION: Injections of Dysport and BOTOX at an equivalence ratio of 2.5:1 U, respectively, applied at the same volume and depth, using the same technique resulted in similar action halos with regard to muscular and sweat gland activity. Both products seem to be safe and very predictable.

Mesh:

Substances:

Year:  2007        PMID: 18053050     DOI: 10.1111/j.1524-4725.2007.34008.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  13 in total

1.  Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.

Authors:  Mark S Nestor; Glynis R Ablon
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  Trends in the Use of Neurotoxins and Dermal Fillers by US Physicians.

Authors:  Laura F Sandoval; Karen E Huang; Scott A Davis; Steven R Feldman; Sarah L Taylor
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

3.  Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.

Authors:  Sheila C Barbarino; Jani A J van Loghem; Cheryl M Burgess; Niamh Corduff
Journal:  J Clin Aesthet Dermatol       Date:  2021-08-01

Review 4.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

5.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

Review 6.  Botulinum toxin: bioweapon & magic drug.

Authors:  Ram Kumar Dhaked; Manglesh Kumar Singh; Padma Singh; Pallavi Gupta
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

7.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

8.  Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis.

Authors:  Hanan Mohamed El Kahky; Heba Mahmoud Diab; Dalia Gamal Aly; Nehal Magdi Farag
Journal:  Dermatol Res Pract       Date:  2013-10-22

Review 9.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

10.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.